New managing director takes over

Arcinova, a Quotient Sciences company, named Dr Christian Dowdeswell as its new managing director at the beginning of August.

He takes over from co-founder and CEO Paul Ryan, who recently announced his resignation. Arcinova plans to refocus its efforts on providing integrated services in the field of active ingredients and early-stage drug products for global biotech and pharmaceutical partners.

Dowdeswell brings more than 25 years of industry experience to his new position, moving to Arcinova from consulting and management roles at companies such as Nanoform and Pangaea Life Sciences. Previously, he was Chief Business Officer Drug Substances at global life sciences company Siegfried AG and held various leadership positions at Lonza, most recently as Vice President and Global Head of Commercial Development for Lonza’s small molecule custom manufacturing business.

This change in management comes at a time when Arcinova has completed a £6.3 million investment in its Alnwick site to expand GMP manufacturing and aseptic capabilities to support early development through proof of concept.